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OBJECTIVES: The purpose of this study is (1) to build
a pharmacoeconomic model to appropriately represent
the outcomes of a single dose almotriptan treatment 
in migraine patients, and (2) to assess the cost-beneﬁt of
almotriptan compared to placebo based on clinical trial
results.
METHODS: Cost-beneﬁt analyses from a societal 
perspective are performed. Time horizon of the model is
deﬁned as a single migraine episode, lasting one workday.
The probabilities of individual events are based on 
clinical trial data published by Pascual et al (2000).
Healthcare consumption probabilities, the likelihood of a
physician or ER (emergency room) visits were drawn
from Adelman et al (1996). Health care cost data are
drawn from Hu et al (1999), who studied speciﬁcally 
the migraineurs’ health care costs. Almotriptan cost is
assumed to be equal to that of sumatriptan because
almotriptan was not yet marketed in the USA at the time
the analysis was performed. In order to evaluate the
beneﬁt from treatment, productivity gain/loss was 
converted to monetary terms using the average market
wage in the United States. Average wage data are drawn
from the Statistical Abstract of the United States, 1999.
All health utilization costs and average daily wage were
converted to year 2000 dollars using consumer price
index (3%). The outcome measure for the cost-beneﬁt
model is net-beneﬁt.
RESULTS: Based on the model used in this study,
almotriptan is more cost-beneﬁcial than placebo, the 
difference of net-beneﬁt being $10.62. Breakeven point is
reached at the price of $26.62 for almotriptan. Placebo
will become more beneﬁcial than almotriptan when
almotriptan cost $26.52 and above.
CONCLUSIONS: Even though a relatively large placebo
effect is observed in migraine treatment, when almo-
triptan price is $26.62 and below, almotriptan is the 
preferred choice of treatment to society over placebo
treatment considering net-beneﬁt.
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OBJECTIVES: To investigate the prescribing patterns of
fentanyl transdermal system and oxycodone HCL con-
trolled-release for chronic nonmalignant pain indications
in the Veterans Administration System. A secondary
objective was to estimate the incremental cost savings if
transdermal fentanyl were used more frequently.
METHODS: A retrospective analysis of the prescription,
inpatient and outpatient treatment ﬁles of the VISN-10
(Ohio) VA database from June 1996 to June 2001 was
conducted. Subjects were included if they received at least
90-days supply of medication and excluded if they were
treated for a malignancy. Potential cost impact was 
estimated by converting all oxycodone HCL controlled-
release prescriptions to transdermal fentanyl, based on
the recommended initial dosing conversion, and calculat-
ing the difference in cost between the two scenarios.
RESULTS: 1,917 transdermal fentanyl and 1,301 
oxycodone HCL controlled-release prescriptions were
written during the study period. Transdermal fentanyl
users were slightly older (59 vs. 52 years) and had a
similar chronic disease index score (6.9 vs. 6.6). The
average dose of transdermal fentanyl was 54mcg/hr 
and oxycodone HCL controlled-release was 66mg/day.
Transdermal fentanyl patients received an average of 
one patch every 2.9 days (manufacturer recommends one
patch every 3 days). Oxycodone HCL controlled-release
patients received an average of 3.3 doses per day (manu-
facturer recommends two doses daily). Using transdermal
fentanyl in place of oxycodone HCL controlled-release
could potentially result in a cost savings of $43,900 over
the study period, or $1.20 per patient per day of therapy.
CONCLUSION: The dosing frequency of transdermal
fentanyl was observed to be consistent with prescribing
information (ie, one patch every 2.9 days, or a 4% excess
above the PI), whereas the dosing frequency of oxycodone
HCL controlled-release exceeded the PI by 65% (ie, 3.3
doses per day). Using transdermal fentanyl instead of 
oxycodone HCL controlled-release has potential to
reduce pharmacy costs.
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OBJECTIVES: The study tests the hypothesis that 
physicians and patients value “quality-of-life” beneﬁts
more highly than managed care decision makers. In con-
ducting this test, we focus on the treatment of migraine
headaches, a therapeutic area for which current drugs
exhibit a wide range of costs and beneﬁts.
METHODS: To test the hypothesis, we conducted
surveys and conjoint exercises with physicians (N = 10),
patients (N = 26) and MCO formulary managers (N = 5).
Conjoint analysis is a survey-based technique for objec-
tively measuring willingness to trade off different product
(or service) attributes.
RESULTS: We found that both patients and their physi-
cians are willing to spend four to ﬁve times more than
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MCO formulary managers for a migraine treatment that
has a good chance of relieving pain within 15 minutes,
allowing quick return to normal activities. We also found
that patients and physicians are willing to pay much more
than MCO formulary managers for other quality-of-life
beneﬁts, including preferred dosage form, nausea relief
and avoiding drowsiness.
CONCLUSIONS: The results support our hypothesis that
physicians and patients value quality-of-life beneﬁts more
highly than MCO formulary managers. However, the
sample sizes involved are too small to permit strong 
inference.
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Despite insomnia induces a great number of medical and
psychiatric visits, the role of co-morbidity in the medical
and professional consequences of this sleep disorder is
poorly documented.
OBJECTIVES: Our study seeks to evaluate the impact of
insomnia on the health status and absenteeism; and 
to identify the part of co-morbidity in the severity of
insomnia.
METHODS: We used data from the Gazel cohort (a
cohort of employees of the French electrical and gas
company) providing medical, professional and demo-
graphic information; the Epworth sleepiness scale; the
Nottingham Health Proﬁle; the Basic Nordic Sleep Ques-
tionnaire and a 3-week sleep log. Firstly, we compared a
group of insomniacs (n = 986) with another one free of
sleep complaints (n = 584). Secondly, all subjects suffer-
ing from mood and organic sleep complaints (snoring and
nocturnal periodic leg movements) were excluded.
RESULTS: In the non-adjusted by mood and organic
sleep complaints comparison (n = 986) we found a higher
absenteeism than in insomniac group than in control (9.6
+/- 31 days versus 5.8 +/- 19 days, U Mann-Withney, 
p < 0.01). However, no differences (6.39 vs. 6.02 days, 
U Mann-Withney, p = NS) in absenteeism between the
control group and insomniacs free of depression or
organic sleep complaints were observed. Nevertheless,
insomniacs (complaining or not of mood or organic sleep
complaints) showed a poorer health status deﬁned by the
Nottingham Health Proﬁle than control subjects.
CONCLUSIONS: Insomniac complaints are strongly
associated with an alteration of quality of life. Absen-
teeism in insomniacs is related to associated mood 
disorders or organic sleep complaints.
NEUROLOGICAL/PAIN DISORDERS—Health
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OBJECTIVE: A French national epidemiological study 
on migraine was presented 10 years ago at the Migraine
trust. It was the ﬁrst study to cover an entire country
(HENRY P. et al.: Migraine prevalence in France. In New
advances in headache research: 2. Ed. Clifford Rose 1991
Smith Gordon-pp.: 11–14). This study has provided also
data on the burden of migraine in terms of its economic
and social impact. We would like today to update the
data.
METHODS: 1486 persons, aged over 15 and suffering
from headaches were randomly selected from a large 
representative sample of the French population. They
were asked to complete a questionnaire, which allowed 
discriminating sufferers of migraine according to IHS 
criteria.
RESULTS: Among the 1486 headache sufferers, we ﬁnd
880 migrainous people (1-1, 1-2 and 1-7 IHS criteria),
454 without migrainous headache and 152 with chronic
daily headache. If we compare the results of the certain
migraine group (1-1 and 1-2 IHS) we ﬁnd that they are
identical (8.1% (1989) versus 8.2% (1999)). However, if
we include the migrainous disorder group fulﬁlling all 
criteria but one (1-7 IHS), the prevalence rate for
migraine headache in France between 1989 and 1999
seems to show a clear increase, rising from 12.1% to
17.3% because of less restrictive criteria than those
applied ten years ago. Regarding the prevalence in general
population for chronic daily headache the rate is around
3% with 1.8% for men and 3.9% for women in 1999.
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OBJECTIVES: To identify through retrospective analy-
sis the difference in Glatiramer Acetate (Copaxone®)
therapy compliance between participants associated with
